Skip to main content
. 2010 Jan 20;2010(1):CD003897. doi: 10.1002/14651858.CD003897.pub3

Chen 2003.

Methods RCT
Participants

  • Single centre

  • China

  • Sensitised kidney transplant recipients ( PRA > 20%)

  • Number (treatment/control):50 (17/33)

  • Age and sex: NS
Interventions Treatment group

  • Daclizumab: 2 doses over 2 weeks


Control group

  • Nothing


Baseline immunosuppression

  • CSA dose: NS

  • MMF dose: NS

  • Steroid dose: NS
Outcomes

  • Mortality

  • Graft loss

  • Acute rejection
Notes

  • 1 year follow‐up

  • Abstract only data available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Stated "randomised", no further information provided
Allocation concealment (selection bias) Unclear risk No stated
Blinding (performance bias and detection bias) 
 Objective outcomes Unclear risk Not stated
Blinding (performance bias and detection bias) 
 Subjective outcomes Unclear risk Not stated
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Primary outcomes for this review (death, graft loss and acute rejection) have been reported. Data only available from 2 conference proceedings abstracts
Other bias Unclear risk Funding source not stated. Data only available from 2 abstracts